The impact of hypoxia on B cells in COVID-19.
The impact of hypoxia on B cells in COVID-19.
复制标题
DOI:
10.1016/j.ebiom.2022.103878
复制
发表时间:
2022-03
期刊:
影响因子:
11.1
通讯作者:
Smith KGC
中科院分区:
文献类型:
--
作者:
Kotagiri P;Mescia F;Hanson AL;Turner L;Bergamaschi L;Peñalver A;Richoz N;Moore SD;Ortmann BM;Dunmore BJ;Morgan MD;Tuong ZK;Cambridge Institute of Therapeutic Immunology and Infectious Disease-National Institute of Health Research (CITIID-NIHR) COVID BioResource Collaboration;Göttgens B;Toshner M;Hess C;Maxwell PH;Clatworthy MR;Nathan JA;Bradley JR;Lyons PA;Burrows N;Smith KGC
Prominent early features of COVID-19 include severe, often clinically silent, hypoxia and a pronounced reduction in B cells, the latter important in defence against SARS-CoV-2. This presentation resembles the phenotype of mice with VHL-deficient B cells, in which Hypoxia-Inducible Factors are constitutively active, suggesting hypoxia might drive B cell abnormalities in COVID-19. Detailed B cell phenotyping was undertaken by flow-cytometry on longitudinal samples from patients with COVID-19 across a range of severities (NIHR Cambridge BioResource). The impact of hypoxia on the transcriptome was assessed by single-cell and whole blood RNA sequencing analysis. The direct effect of hypoxia on B cells was determined through immunisation studies in genetically modified and hypoxia-exposed mice. We demonstrate the breadth of early and persistent defects in B cell subsets in moderate/severe COVID-19, including reduced marginal zone-like, memory and transitional B cells, changes also observed in B cell VHL-deficient mice. These findings were associated with hypoxia-related transcriptional changes in COVID-19 patient B cells, and similar B cell abnormalities were seen in mice kept in hypoxic conditions. Hypoxia may contribute to the pronounced and persistent B cell pathology observed in acute COVID-19 pneumonia. Assessment of the impact of early oxygen therapy on these immune defects should be considered, as their correction could contribute to improved outcomes. Evelyn Trust, Addenbrooke's Charitable Trust, UKRI/NIHR, Wellcome Trust
登录
查看更多内容
影响因子:
64.8
作者:
Cho, Sung Hoon;Raybuck, Ariel L.;Stengel, Kristy;Wei, Mei;Beck, Thomas C.;Volanakis, Emmanuel;Thomas, James W.;Hiebert, Scott;Haase, Volker H.;Boothby, Mark R.
通讯作者:
Boothby, Mark R.
影响因子:
56.9
作者:
Chakraborty, Abhishek A.;Laukka, Tuomas;Kaelin, William G., Jr.
通讯作者:
Kaelin, William G., Jr.
DOI:
10.1016/j.cmi.2020.10.021
发表时间:
2021-03
期刊:
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
影响因子:
--
作者:
Ripa M;Galli L;Poli A;Oltolini C;Spagnuolo V;Mastrangelo A;Muccini C;Monti G;De Luca G;Landoni G;Dagna L;Clementi M;Rovere Querini P;Ciceri F;Tresoldi M;Lazzarin A;Zangrillo A;Scarpellini P;Castagna A;COVID-BioB study group
通讯作者:
COVID-BioB study group
影响因子:
32.4
作者:
Bergamaschi L;Mescia F;Turner L;Hanson AL;Kotagiri P;Dunmore BJ;Ruffieux H;De Sa A;Huhn O;Morgan MD;Gerber PP;Wills MR;Baker S;Calero-Nieto FJ;Doffinger R;Dougan G;Elmer A;Goodfellow IG;Gupta RK;Hosmillo M;Hunter K;Kingston N;Lehner PJ;Matheson NJ;Nicholson JK;Petrunkina AM;Richardson S;Saunders C;Thaventhiran JED;Toonen EJM;Weekes MP;Cambridge Institute of Therapeutic Immunology and Infectious Disease-National Institute of Health Research (CITIID-NIHR) COVID BioResource Collaboration;Göttgens B;Toshner M;Hess C;Bradley JR;Lyons PA;Smith KGC
通讯作者:
Smith KGC
DOI:
10.1073/pnas.0605944103
发表时间:
2006-09-12
影响因子:
11.1
作者:
Hobeika, E.;Thiemann, S.;Reth, M.
通讯作者:
Reth, M.